Climb Bio CLYM116 Phase 1 data back every-12-week dosing in IgAN

Climb Bio has released initial Phase 1 data for CLYM116, its anti-APRIL monoclonal antibody in development for IgA nephropathy, reporting near-complete suppression of the target cytokine following a single dose and a half-life that the company says is approximately threefold longer than a key comparator in the space.

The data come from a randomised, double-blind, placebo-controlled single- and multiple-ascending-dose study enrolling 46 healthy volunteers. A single 320 mg subcutaneous dose produced greater than 90% suppression of free APRIL and drove reductions of 60 to 75% in IgA, Gd-IgA1, and IgM, with those reductions maintained through 12 weeks. The projected half-life of approximately 29 days, derived from the multiple-ascending-dose cohort, is the figure Climb Bio uses to underpin its case for an every-12-week dosing regimen. No serious adverse events, dose-limiting toxicities, or cases of hypogammaglobulinaemia were reported.

The mechanism and the competitive claim

CLYM116 uses what Climb Bio describes as a pH-dependent "sweeper" mechanism. Rather than simply binding APRIL, the antibody is designed to facilitate its lysosomal degradation while recycling itself, which the company says extends its pharmacological duration. Aoife Brennan, president and chief executive, said the design was intended to "raise the bar on how completely and how durably" APRIL can be suppressed, and that the early data support a best-in-class profile against existing agents in the class.

The comparison to sibeprenlimab, the anti-APRIL antibody developed by Vistara Therapeutics and licensed to AstraZeneca, is the central competitive reference in the release. Climb Bio claims a roughly threefold longer half-life, though the company's forward-looking statements caution that cross-trial comparisons may not be reliable given differences in design and participant characteristics. No head-to-head study has been conducted.

Phase 2 and the path to registration

Climb Bio's ongoing NAVIGATE-2 Phase 2 study is an open-label randomised trial evaluating an 800 mg loading dose of CLYM116 followed by either 400 mg every eight weeks or 400 mg every 12 weeks. The trial is intended to confirm which dosing regimen advances into a pivotal programme. The company anticipates initial NAVIGATE-2 data in the first half of 2027 and says it plans to initiate a Phase 3 registrational study the same year, subject to data readout.

On the formulation side, Climb Bio has completed development of a high-concentration 200 mg per mL presentation that allows a 400 mg dose to be delivered in a single subcutaneous injection. Pre-filled syringe development is complete, and an autoinjector is in development for the commercial launch.

IgA nephropathy has become one of the more competitive areas within nephrology-focused immunology. The complement pathway and the APRIL/BAFF axis are both validated targets, with approved agents including sparsentan and iptacopan on the market and a growing pipeline of later-stage candidates. The appeal of less frequent dosing is real in a chronic disease requiring long-term treatment, and Climb Bio's quarterly-dosing thesis, if supported in Phase 2, could be a meaningful differentiator. However, APRIL suppression as a surrogate for proteinuria reduction and kidney function preservation will ultimately need to be borne out in a registrational cohort, and the field is watching for the first confirmatory readouts in this mechanistic class.

Additional Phase 1 data and initial results from a Beijing Mabworks healthy-volunteer study conducted in China are expected to be presented at a medical meeting in the fourth quarter of 2026.